Detalhe da pesquisa
1.
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer.
N Engl J Med
; 386(22): 2112-2119, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35648703
2.
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
J Transl Med
; 21(1): 508, 2023 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507765
3.
Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Cancer
; 127(24): 4565-4573, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34547103
4.
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply.
N Engl J Med
; 387(6): 574, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35947721
5.
The role of antimicrobial prophylaxis in patients with head and neck cancer undergoing chemoradiation.
J Oncol Pharm Pract
; 26(3): 580-586, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31288635
6.
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Int J Biol Sci
; 20(5): 1578-1601, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38481806
7.
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
Cancer Immunol Res
; 12(3): 322-333, 2024 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38147316
8.
Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
Genes Chromosomes Cancer
; 51(4): 384-93, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22170739
9.
The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis.
Genes Chromosomes Cancer
; 51(5): 473-9, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22302717
10.
Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.
Clin Cancer Res
; 29(12): 2173-2175, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040070
11.
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies.
bioRxiv
; 2023 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36711504
12.
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
J Immunother Cancer
; 11(10)2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37907221
13.
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504.
Int J Radiat Oncol Biol Phys
; 115(4): 847-860, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36228746
14.
Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.
Front Oral Health
; 3: 902160, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35937775
15.
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors.
Clin Cancer Res
; 28(3): 479-488, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34753777
16.
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck.
Oral Oncol
; 135: 106183, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36215771
17.
A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection.
Oncotarget
; 12(13): 1201-1213, 2021 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34194619
18.
Explant Modeling of the Immune Environment of Head and Neck Cancer.
Front Oncol
; 11: 611365, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34221953
19.
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
J Immunother Cancer
; 9(5)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963014
20.
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Nat Commun
; 12(1): 1047, 2021 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33594075